ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Bibliometric analysis of Pseudomonas aeruginosa vaccine development highlighting research status, evolution, and future opportunities.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Pseudomonas aeruginosa (P. aeruginosa) is a predominant pathogen responsible for severe nosocomial infections, with rising multidrug resistance posing a critical threat to global health. Despite the promise of vaccination, antigenic diversity and complex virulence mechanisms involving multiple biomacromolecules have impeded the development of an effective vaccine. This study aims to map the research landscape of P. aeruginosa vaccine development. A comprehensive bibliometric analysis of 1701 publications from the Web of Science (WOS) and PubMed database (1970-2025) was conducted using VOSviewer and CiteSpace. A pronounced increase in annual publication output following 2013 was observed, with the USA and China identified as the principal contributors. Keyword clustering and burst detection analyses revealed emerging research foci on multi-epitope vaccine constructs, biomacromolecule-based antigen design, including outer membrane proteins, polysaccharides, and vesicles, and innovative delivery platforms such as nanoparticles. Contemporary investigations emphasize structural vaccinology, reverse immunology methodologies, and the application of biodegradable polymers for antigen encapsulation. Overall, this study reveals shifting research priorities and offers a data-driven framework to inform future research directions of P. aeruginosa vaccine development. Notably, the convergence of computational vaccine design with advanced macromolecular delivery systems presents substantial promise for the development of broadly protective vaccines against P. aeruginosa.
Indexed as
Identifiers
41498839What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.